Growth Metrics

Sonoma Pharmaceuticals (SNOA) Receivables - Net (2016 - 2025)

Sonoma Pharmaceuticals has reported Receivables - Net over the past 15 years, most recently at $2.4 million for Q4 2025.

  • For Q4 2025, Receivables - Net fell 0.96% year-over-year to $2.4 million; the TTM value through Dec 2025 reached $2.4 million, down 0.96%, while the annual FY2025 figure was $2.2 million, 23.69% down from the prior year.
  • Receivables - Net for Q4 2025 was $2.4 million at Sonoma Pharmaceuticals, down from $2.7 million in the prior quarter.
  • Over five years, Receivables - Net peaked at $3.4 million in Q3 2021 and troughed at $2.2 million in Q3 2023.
  • A 5-year average of $2.7 million and a median of $2.6 million in 2023 define the central range for Receivables - Net.
  • Biggest five-year swings in Receivables - Net: tumbled 37.2% in 2021 and later skyrocketed 42.02% in 2024.
  • Year by year, Receivables - Net stood at $2.9 million in 2021, then decreased by 19.52% to $2.3 million in 2022, then rose by 25.21% to $2.9 million in 2023, then dropped by 16.38% to $2.4 million in 2024, then decreased by 0.96% to $2.4 million in 2025.
  • Business Quant data shows Receivables - Net for SNOA at $2.4 million in Q4 2025, $2.7 million in Q3 2025, and $2.6 million in Q2 2025.